Literature DB >> 21492876

The effect of hepatic ischemia reperfusion injury in a murine model of nonalcoholic steatohepatitis.

Amit D Tevar1, Callisia N Clarke, Rebecca Schuster, Jiang Wang, Michael J Edwards, Alex B Lentsch.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) refers to an increasingly diagnosed condition involving triglyceride accumulation into hepatocytes resulting in a broad spectrum of liver injury. The progression of NAFLD, a relatively benign condition, to nonalcoholic steatohepatitis (NASH) involves the hepatic infiltration of inflammatory cells and subsequent hepatocellular injury. Ischemia/reperfusion (I/R) injury of the liver is a major complication of liver resection, hepatic trauma, and liver transplantation. To date, there have been no studies that have evaluated the effects of hepatic I/R on models of NASH.
OBJECTIVE: Evaluate the effects of hepatic I/R on a mouse model of NASH.
METHODS: A mouse model of progressive NASH was developed and evaluated using C57BL/6 mice fed a methionine choline deficient diet for 3, 6, 9, and 12 wk. Mice subsequently underwent 90 min of partial hepatic ischemia with reperfusion of 1, 4, and 8 h. Mice were sacrificed after the indicated periods, and blood and liver samples were taken for analysis.
RESULTS: Mice fed the MCD diet showed a rapid induction of hepatic steatosis, inflammation, and fibrosis by 3 wk that persisted over the 12-wk period of diet, as demonstrated by histologic examination, alanine aminotransferase (ALT), and liver content of myeloperoxidase (MPO). The response to I/R in livers with progressive NASH fed MCD diet for 3, 6, 9, and 12 wk showed marked neutrophil recruitment and hepatocyte necrosis.
CONCLUSION: These data suggest the inflammatory response from I/R is augmented in livers with NASH histopathology compared with normal liver.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21492876      PMCID: PMC4599341          DOI: 10.1016/j.jss.2011.01.056

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  23 in total

1.  Short-term administration of (-)-epigallocatechin gallate reduces hepatic steatosis and protects against warm hepatic ischemia/reperfusion injury in steatotic mice.

Authors:  Ryan N Fiorini; Jennifer L Donovan; David Rodwell; Zachary Evans; Gang Cheng; Harold D May; Charles E Milliken; John S Markowitz; Crystal Campbell; Julia K Haines; Michael G Schmidt; Kenneth D Chavin
Journal:  Liver Transpl       Date:  2005-03       Impact factor: 5.799

2.  The outcome of steatotic grafts in liver transplantation.

Authors:  R Adam; M Reynes; M Johann; M Morino; I Astarcioglu; I Kafetzis; D Castaing; H Bismuth
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

3.  Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and KC.

Authors:  A B Lentsch; H Yoshidome; W G Cheadle; F N Miller; M J Edwards
Journal:  Hepatology       Date:  1998-04       Impact factor: 17.425

4.  Ischemic preconditioning increases the tolerance of Fatty liver to hepatic ischemia-reperfusion injury in the rat.

Authors:  Anna Serafín; Joan Roselló-Catafau; Neus Prats; Carme Xaus; Emilio Gelpí; Carmen Peralta
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

5.  Expression of the CXC chemokine receptor 3 and its ligands in ischemia-reperfusion injury of liver in rats.

Authors:  Z Liu; W Xu; X Zhang; D Cui; B Liu
Journal:  Transplant Proc       Date:  2008-06       Impact factor: 1.066

6.  The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance.

Authors:  Mary E Rinella; Richard M Green
Journal:  J Hepatol       Date:  2004-01       Impact factor: 25.083

7.  Risk factors for primary dysfunction after liver transplantation--a multivariate analysis.

Authors:  R J Ploeg; A M D'Alessandro; S J Knechtle; M D Stegall; J D Pirsch; R M Hoffmann; T Sasaki; H W Sollinger; F O Belzer; M Kalayoglu
Journal:  Transplantation       Date:  1993-04       Impact factor: 4.939

Review 8.  Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  J Gastroenterol Hepatol       Date:  2007-06       Impact factor: 4.029

9.  Ischemic preconditioning affects interleukin release in fatty livers of rats undergoing ischemia/reperfusion.

Authors:  Anna Serafín; Joan Roselló-Catafau; Neus Prats; Emilio Gelpí; Joan Rodés; Carmen Peralta
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

10.  Reduced inflammatory response and increased microcirculatory disturbances during hepatic ischemia-reperfusion injury in steatotic livers of ob/ob mice.

Authors:  Tadashi Hasegawa; Yoshiya Ito; Jayanthika Wijeweera; Jie Liu; Ernst Malle; Anwar Farhood; Robert S McCuskey; Hartmut Jaeschke
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-02-15       Impact factor: 4.052

View more
  5 in total

Review 1.  Liver transplantation and nonalcoholic fatty liver disease.

Authors:  Kymberly D Watt
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-09-25

2.  Endoplasmic reticulum stress and lipid metabolism: mechanisms and therapeutic potential.

Authors:  Sana Basseri; Richard C Austin
Journal:  Biochem Res Int       Date:  2011-12-13

3.  Interleukin-33 / Cyclin D1 imbalance in severe liver steatosis predicts susceptibility to ischemia reperfusion injury.

Authors:  Kelley G Núñez; Anderson Frank; Janet Gonzalez-Rosario; Gretchen Galliano; Kim Bridle; Darrell Crawford; John Seal; Frank Abbruscato; Himanshu Vashistha; Paul T Thevenot; Ari J Cohen
Journal:  PLoS One       Date:  2019-04-29       Impact factor: 3.240

4.  Scutellarin attenuates hypoxia/reoxygenation injury in hepatocytes by inhibiting apoptosis and oxidative stress through regulating Keap1/Nrf2/ARE signaling.

Authors:  Haiyuan Wu; Lan Jia
Journal:  Biosci Rep       Date:  2019-11-29       Impact factor: 3.840

5.  Pharmacological myeloperoxidase (MPO) inhibition in an obese/hypertensive mouse model attenuates obesity and liver damage, but not cardiac remodeling.

Authors:  Arnold Piek; Debby P Y Koonen; Elisabeth-Maria Schouten; Eva L Lindtstedt; Erik Michaëlsson; Rudolf A de Boer; Herman H W Silljé
Journal:  Sci Rep       Date:  2019-12-10       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.